CEL-SCI Corporation (NYSE American: CVM) announced the pricing of a best-efforts offering of 2.5 million shares of common stock at $1.00 per share. The clinical stage cancer immunotherapy company expects to raise $2.5 million in gross proceeds before deducting placement agent fees and offering expenses.

The offering is expected to close on June 16, 2026, subject to customary closing conditions. ThinkEquity serves as the sole placement agent for the transaction.

CEL-SCI plans to use the proceeds for continued development of Multikine, general corporate purposes, and working capital. Multikine is an investigational cancer immunotherapy designed to boost patients' immune systems before surgery, radiotherapy, and chemotherapy.

The securities are being offered under a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on July 3, 2025, and declared effective on August 12, 2025.

The Vienna, Virginia-based company has dosed Multikine in over 740 patients. The treatment received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.